When you look at the trials, most trials either exclude older adults, or if they include them, very few are over the age of 65, and even fewer are over the age of 75, Batsis said
Key players driving the GLP-1 market include Novo Nordisk, Eli Lilly, Pfizer, AstraZeneca, Roche, Sanofi, Boehringer Ingelheim, and Tonghua Dongbao Pharmaceutical
If hot flashes remain troublesome despite weight management, evidence-based treatments specifically targeting vasomotor symptoms should be considered
However, these factors are secondary to temperature
Over time, researchers will gain a clearer picture of the potential long-term risks
Why Side Effects Are Usually Worse at the Beginning The dose escalation schedule used with GLP-1 medications is specifically designed to reduce side effect burden by allowing the body time to adapt before the dose increases